ORIGINAL ARTICLE
Open Access

Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis

James R. Whitmore 1, Sarah L. Thompson1, Daniel P. HarringtonORCID 2

1Department of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
2NIHR Biomedical Research Centre, University College London (UCL) Institute of Ophthalmology, London, United Kingdom.
DOI: 10.18081/ajbm.2025.4.383

Publication History: Received 29 September 2025, Revised 27 October 2025, Accepted 19 November 2025, Available online 12 December 2025
Copyright: © 2025 Harrington, et al. This is an open-access article under a Creative Commons license (CC BY 4.0).
Crossmark logo

ABSTRACT

Background

Diabetic macular edema (DME) is a leading cause of vision loss among working-age adults and represents a major burden on retinal services within the United Kingdom’s National Health Service (NHS). While randomized controlled trials have established the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, real-world outcomes may differ due to variations in patient characteristics, treatment intensity, and service delivery. This study aimed to evaluate the effectiveness of anti-VEGF therapy for DME in routine NHS clinical practice.

Methods

A retrospective, multicenter, real-world cohort analysis was conducted using electronic medical record data from NHS hospital eye services. Adult patients with center-involving DME who initiated intravitreal anti-VEGF therapy (aflibercept, ranibizumab, or bevacizumab) between January 2018 and December 2023 were included. The primary outcome was change in best-corrected visual acuity (BCVA) at 12 months, measured in ETDRS letters. Secondary outcomes included changes in central retinal thickness (CRT), injection frequency, and treatment persistence.

Results

A total of 642 eyes from 642 patients were analyzed (mean age 64.8 ± 9.7 years; 58.1% male). Mean BCVA improved from 61.2 ± 13.9 ETDRS letters at baseline to 67.9 ± 14.1 letters at 12 months, representing a mean gain of +6.7 letters (p < 0.001). Visual gains of ≥10 and ≥15 letters were achieved in 34.6% and 18.9% of eyes, respectively. Mean CRT decreased by 117 μm over 12 months (p < 0.001). Eyes treated with aflibercept demonstrated greater visual and anatomical improvement compared with ranibizumab and bevacizumab. The mean number of injections during the first year was 7.1 ± 2.4. Lower baseline visual acuity and higher injection frequency were independent predictors of greater visual improvement.

Conclusion

In routine NHS practice, intravitreal anti-VEGF therapy provides meaningful visual and anatomical benefits for patients with DME, although outcomes are more modest than those reported in clinical trials. Treatment intensity and baseline visual acuity remain key determinants of response. These real-world findings support the effectiveness of anti-VEGF therapy in DME and highlight the importance of optimizing service delivery and adherence to maximize patient outcomes.

Keywords: Diabetic macular edema; Anti-VEGF; Real-world evidence; NHS; Visual acuity; Optical coherence tomograph

Recommended Citation

Whitmore JR, Thompson SL, Harrington DP. Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis. Advanced Journal of Biomedicine & Medicine. 2025;13(4):383-398. doi:10.18081/ajbm.2025.4.383

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

References

  1. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. 1995;102(1):7–16. doi:10.1016/S0161-6420(95)31052-4
  2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. 2010;376(9735):124–136. doi:10.1016/S0140-6736(09)62124-3
  3. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the RISE and RIDE studies. 2013;120(10):2013–2022. doi:10.1016/j.ophtha.2013.02.034
  4. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039
  5. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. 2014;121(11):2247–2254. doi:10.1016/j.ophtha.2014.05.006
  6. Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. 2014;121(5):1045–1053. doi:10.1016/j.ophtha.2013.11.041
  7. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi:10.1056/NEJMoa1414264
  8. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. 2016;123(6):1351–1359. doi:10.1016/j.ophtha.2016.02.022
  9. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. 2016;123(11):2376–2385. doi:10.1016/j.ophtha.2016.07.032
  10. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser for diabetic macular edema. 2010;117(6):1064–1077. doi:10.1016/j.ophtha.2010.02.031
  11. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. 2011;118(4):615–625. doi:10.1016/j.ophtha.2011.01.031
  12. Chakravarthy U, Williams M, Group UKAMDEMR. The Royal College of Ophthalmologists National Ophthalmology Database study of ranibizumab for diabetic macular edema. Eye (Lond). 2016;30(6):812–819. doi:10.1038/eye.2016.34
  13. Johnston RL, Donachie PHJ, Sallam A, et al. Real-world outcomes of anti-VEGF therapy in diabetic macular edema in the UK. Br J Ophthalmol. 2016;100(8):1052–1056. doi:10.1136/bjophthalmol-2015-307556
  14. Talks JS, Lotery AJ, Ghanchi F, et al. First-year visual acuity outcomes of anti-VEGF treatment for diabetic macular edema in routine clinical practice. Eye (Lond). 2016;30(5):702–708. doi:10.1038/eye.2016.4
  15. Bressler SB, Glassman AR, Almukhtar T, et al. Five-year outcomes of diabetic macular edema treated with anti-VEGF therapy. 2018;125(11):1773–1780. doi:10.1016/j.ophtha.2018.04.010
  16. Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to anti-VEGF therapy for persistent diabetic macular edema. 2018;125(6):839–847. doi:10.1016/j.ophtha.2017.11.019
  17. Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond VEGF. Prog Retin Eye Res. 2018;63:20–68. doi:10.1016/j.preteyeres.2017.10.002
  18. National Institute for Health and Care Excellence (NICE). Aflibercept for treating diabetic macular oedema. NICE technology appraisal guidance TA346. Published 2015.
  19. National Institute for Health and Care Excellence (NICE). Ranibizumab for treating diabetic macular oedema. NICE technology appraisal guidance TA274. Published 2013.
  20. Holekamp NM. Review of neovascular age-related macular degeneration treatment options. Am J Manag Care. 2019;25(10 Suppl):S172–S181. doi:10.37765/ajmc.2019.88527
  21. Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of faricimab in diabetic macular edema. 2022;129(7):e78–e87. doi:10.1016/j.ophtha.2022.02.012
  22. World Health Organization. Global report on diabetes. Geneva: WHO; 2016. doi:10.1002/9780470670516.wbeog167
  23. Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with diabetic macular edema. JAMA Ophthalmol. 2014;132(11):1309–1316. doi:10.1001/jamaophthalmol.2014.2350
  24. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery corticosteroid implants: expanding the treatment options for diabetic macular edema. 2014;231(3):131–142. doi:10.1159/000357430
  25. Wong TY, Sabanayagam C. Strategies to tackle the global burden of diabetic retinopathy: from epidemiology to artificial intelligence. 2020;243(1):9–20. doi:10.1159/000502387

2025 Vol 13, Issue 4 Pages 383-398

Download article

PDF Download: 330

PDF (466.0 KB) XML (4.4 KB)

Cite this article

James R. Whitmore, Sarah L. Thompson, Daniel P. Harrington (2025). Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis<br /> . Advanced Journal of Biomedicine & Medicine, 13(4), 383-398. https://doi.org/10.18081/ajbm.2025.4.383
James R. Whitmore, Sarah L. Thompson, Daniel P. Harrington. "Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis<br /> ." Advanced Journal of Biomedicine & Medicine, vol. 13, no. 4, 2025, pp. 383-398. DOI: 10.18081/ajbm.2025.4.383.
James R. Whitmore, Sarah L. Thompson, Daniel P. Harrington. Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis<br /> . AJBM. 2025;13(4):383-398. DOI: 10.18081/ajbm.2025.4.383. PMID: .
James R. Whitmore, Sarah L. Thompson, Daniel P. Harrington 2025, "Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis<br /> ", Advanced Journal of Biomedicine & Medicine, vol. 13, no. 4, pp. 383-398.
@article{james2025, title={Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis<br /> }, author={James R. Whitmore, Sarah L. Thompson, Daniel P. Harrington}, journal={Advanced Journal of Biomedicine & Medicine}, volume={13}, number={4}, pages={383-398}, year={2025}, doi={10.18081/ajbm.2025.4.383} }
TY - JOUR AU - James R. Whitmore, Sarah L. Thompson, Daniel P. Harrington TI - Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis<br /> JO - American Journal of Biomedicine VL - 13 IS - 4 SP - 383-398 PY - 2025 DO - 10.18081/ajbm.2025.4.383 ER -
%0 Journal Article %A James R. Whitmore, Sarah L. Thompson, Daniel P. Harrington %T Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis<br /> %J American Journal of Biomedicine %V 13 %N 4 %P 383-398 %D 2025 %R 10.18081/ajbm.2025.4.383 %M
James R. Whitmore, Sarah L. Thompson, Daniel P. Harrington (2025). Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis<br /> . Advanced Journal of Biomedicine & Medicine, 13(4), 383-398. https://doi.org/10.18081/ajbm.2025.4.383

Article metric